Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells

Glioblastoma is the most prevalent and aggressive primary brain tumour for which total tumour lysate-pulsed dendritic cell vaccination is currently under clinical evaluation. Glioblastoma extracellular vesicles (EVs) may represent an enriched cell-free source of tumour-associated (neo-) antigens to...

Full description

Bibliographic Details
Main Authors: Sophie A. Dusoswa, Sophie K. Horrevorts, Martino Ambrosini, Hakan Kalay, Nanne J. Paauw, Rienk Nieuwland, Michiel D. Pegtel, Tom Würdinger, Yvette Van Kooyk, Juan J. Garcia-Vallejo
Format: Article
Language:English
Published: Wiley 2019-12-01
Series:Journal of Extracellular Vesicles
Subjects:
Online Access:http://dx.doi.org/10.1080/20013078.2019.1648995
_version_ 1819001549848838144
author Sophie A. Dusoswa
Sophie K. Horrevorts
Martino Ambrosini
Hakan Kalay
Nanne J. Paauw
Rienk Nieuwland
Michiel D. Pegtel
Tom Würdinger
Yvette Van Kooyk
Juan J. Garcia-Vallejo
author_facet Sophie A. Dusoswa
Sophie K. Horrevorts
Martino Ambrosini
Hakan Kalay
Nanne J. Paauw
Rienk Nieuwland
Michiel D. Pegtel
Tom Würdinger
Yvette Van Kooyk
Juan J. Garcia-Vallejo
author_sort Sophie A. Dusoswa
collection DOAJ
description Glioblastoma is the most prevalent and aggressive primary brain tumour for which total tumour lysate-pulsed dendritic cell vaccination is currently under clinical evaluation. Glioblastoma extracellular vesicles (EVs) may represent an enriched cell-free source of tumour-associated (neo-) antigens to pulse dendritic cells (DCs) for the initiation of an anti-tumour immune response. Capture and uptake of EVs by DCs could occur in a receptor-mediated and presumably glycan-dependent way, yet the glycan composition of glioblastoma EVs is unknown. Here, we set out to characterize the glycocalyx composition of glioblastoma EVs by lectin-binding ELISA and comprehensive immunogold transmission electron microscopy (immuno-TEM). The surface glycan profile of human glioblastoma cell line-derived EVs (50–200 nm) was dominated by α-2,3- and α-2,6 linked sialic acid-capped complex N-glycans and bi-antennary N-glycans. Since sialic acids can trigger immune inhibitory sialic acid–binding Ig-like lectin (Siglec) receptors, we screened for Siglec ligands on the EVs. Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs. Surprisingly, however, glioblastoma EVs lack glycans that could bind Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN, CD209), a receptor that mediates uptake and induction of CD4+ and CD8+ T cell activation. Therefore, we explored whether modification of the EV glycan surface could reduce immune inhibitory Siglec binding, while enhancing EV internalization by DCs in a DC-SIGN dependent manner. Desialylation with a pan-sialic acid hydrolase led to reduction of sialic acid expression on EVs. Moreover, insertion of a high-affinity ligand (LewisY) for DC-SIGN resulted in a four-fold increase of uptake by monocyte-derived DCs. In conclusion, we show that the glycocalyx composition of EVs is a key factor of efficient DC targeting and that modification of the EV glycocalyx potentiates EVs as anti-cancer vaccine.
first_indexed 2024-12-20T22:50:59Z
format Article
id doaj.art-a7fc4dd544604f708191b881d750dd2a
institution Directory Open Access Journal
issn 2001-3078
language English
last_indexed 2024-12-20T22:50:59Z
publishDate 2019-12-01
publisher Wiley
record_format Article
series Journal of Extracellular Vesicles
spelling doaj.art-a7fc4dd544604f708191b881d750dd2a2022-12-21T19:24:14ZengWileyJournal of Extracellular Vesicles2001-30782019-12-018110.1080/20013078.2019.16489951648995Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cellsSophie A. Dusoswa0Sophie K. Horrevorts1Martino Ambrosini2Hakan Kalay3Nanne J. Paauw4Rienk Nieuwland5Michiel D. Pegtel6Tom Würdinger7Yvette Van Kooyk8Juan J. Garcia-Vallejo9Amsterdam UMC, Vrije Universiteit AmsterdamAmsterdam UMC, Vrije Universiteit AmsterdamAmsterdam UMC, Vrije Universiteit AmsterdamAmsterdam UMC, Vrije Universiteit AmsterdamAmsterdam UMC, Vrije Universiteit AmsterdamAmsterdam UMC, University of AmsterdamAmsterdam UMC, Vrije Universiteit AmsterdamAmsterdam UMC, Vrije Universiteit AmsterdamAmsterdam UMC, Vrije Universiteit AmsterdamAmsterdam UMC, Vrije Universiteit AmsterdamGlioblastoma is the most prevalent and aggressive primary brain tumour for which total tumour lysate-pulsed dendritic cell vaccination is currently under clinical evaluation. Glioblastoma extracellular vesicles (EVs) may represent an enriched cell-free source of tumour-associated (neo-) antigens to pulse dendritic cells (DCs) for the initiation of an anti-tumour immune response. Capture and uptake of EVs by DCs could occur in a receptor-mediated and presumably glycan-dependent way, yet the glycan composition of glioblastoma EVs is unknown. Here, we set out to characterize the glycocalyx composition of glioblastoma EVs by lectin-binding ELISA and comprehensive immunogold transmission electron microscopy (immuno-TEM). The surface glycan profile of human glioblastoma cell line-derived EVs (50–200 nm) was dominated by α-2,3- and α-2,6 linked sialic acid-capped complex N-glycans and bi-antennary N-glycans. Since sialic acids can trigger immune inhibitory sialic acid–binding Ig-like lectin (Siglec) receptors, we screened for Siglec ligands on the EVs. Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs. Surprisingly, however, glioblastoma EVs lack glycans that could bind Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN, CD209), a receptor that mediates uptake and induction of CD4+ and CD8+ T cell activation. Therefore, we explored whether modification of the EV glycan surface could reduce immune inhibitory Siglec binding, while enhancing EV internalization by DCs in a DC-SIGN dependent manner. Desialylation with a pan-sialic acid hydrolase led to reduction of sialic acid expression on EVs. Moreover, insertion of a high-affinity ligand (LewisY) for DC-SIGN resulted in a four-fold increase of uptake by monocyte-derived DCs. In conclusion, we show that the glycocalyx composition of EVs is a key factor of efficient DC targeting and that modification of the EV glycocalyx potentiates EVs as anti-cancer vaccine.http://dx.doi.org/10.1080/20013078.2019.1648995glioblastomagliomaextracellular vesiclesevglycansdendritic cellsdccancer vaccine
spellingShingle Sophie A. Dusoswa
Sophie K. Horrevorts
Martino Ambrosini
Hakan Kalay
Nanne J. Paauw
Rienk Nieuwland
Michiel D. Pegtel
Tom Würdinger
Yvette Van Kooyk
Juan J. Garcia-Vallejo
Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells
Journal of Extracellular Vesicles
glioblastoma
glioma
extracellular vesicles
ev
glycans
dendritic cells
dc
cancer vaccine
title Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells
title_full Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells
title_fullStr Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells
title_full_unstemmed Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells
title_short Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells
title_sort glycan modification of glioblastoma derived extracellular vesicles enhances receptor mediated targeting of dendritic cells
topic glioblastoma
glioma
extracellular vesicles
ev
glycans
dendritic cells
dc
cancer vaccine
url http://dx.doi.org/10.1080/20013078.2019.1648995
work_keys_str_mv AT sophieadusoswa glycanmodificationofglioblastomaderivedextracellularvesiclesenhancesreceptormediatedtargetingofdendriticcells
AT sophiekhorrevorts glycanmodificationofglioblastomaderivedextracellularvesiclesenhancesreceptormediatedtargetingofdendriticcells
AT martinoambrosini glycanmodificationofglioblastomaderivedextracellularvesiclesenhancesreceptormediatedtargetingofdendriticcells
AT hakankalay glycanmodificationofglioblastomaderivedextracellularvesiclesenhancesreceptormediatedtargetingofdendriticcells
AT nannejpaauw glycanmodificationofglioblastomaderivedextracellularvesiclesenhancesreceptormediatedtargetingofdendriticcells
AT rienknieuwland glycanmodificationofglioblastomaderivedextracellularvesiclesenhancesreceptormediatedtargetingofdendriticcells
AT michieldpegtel glycanmodificationofglioblastomaderivedextracellularvesiclesenhancesreceptormediatedtargetingofdendriticcells
AT tomwurdinger glycanmodificationofglioblastomaderivedextracellularvesiclesenhancesreceptormediatedtargetingofdendriticcells
AT yvettevankooyk glycanmodificationofglioblastomaderivedextracellularvesiclesenhancesreceptormediatedtargetingofdendriticcells
AT juanjgarciavallejo glycanmodificationofglioblastomaderivedextracellularvesiclesenhancesreceptormediatedtargetingofdendriticcells